1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS 22990-19-8 Assay ≥98.5% (HPLC) Factory

Short Description:

Name: 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline

CAS: 22990-19-8

Appearance: White Crystal Powder

Assay: ≥98.5% (HPLC)

Assay: 98.5%~101.0% (on the dried basis)

Intermediate of API (CAS: 242478-38-2) in the treatment of Overactive Bladder (Pollakiuria)

Enquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Commercial Supply Related Intermediates:
CAS: 242478-38-2
(R)-(-)-3-Quinuclidinol CAS: 25333-42-0
(S)-(+)-3-Quinuclidinol CAS: 34583-34-1
3-Quinuclidinone Hydrochloride CAS: 1193-65-3
1-Phenyl-1,2,3,4-Tetrahydro-Isoquinoline CAS: 22990-19-8
(S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS: 118864-75-8

Chemical Properties:

Chemical Name	1-Phenyl-1,2,3,4-Tetrahydroisoquinoline
Synonyms	1,2,3,4-Tetrahydro-1-Phenylisoquinoline
CAS Number	22990-19-8
CAT Number	RF-PI155
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C15H15N
Molecular Weight	209.29
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White Crystal Powder
Single Impurity	≤0.20%
Melting Point	93.0~99.0℃
Loss on Drying	≤0.50%
Assay	≥98.5% (HPLC)
Assay	98.5%~101.0% (on the dried basis)
Test Standard	Enterprise Standard
Usage	(CAS: 242478-38-2) Intermediate

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light & moisture

Advantages:

FAQ:

Application:

API (CAS: 242478-38-2) is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence. (CAS: 242478-38-2) is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. The synthesis of (CAS: 242478-38-2) involves the preparation of racemic 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline via cyclization of N-(2-phenylethyl)benzamide, and subsequent reaction with ethyl chloroformate and transesterification with (R)- 3-Quinuclidinol. Chiral chromatography affords the isolation of the desired diastereomer. Alternatively, 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline may be subjected to optical resolution with (+)-Tartaric Acid prior to treatment with ethyl chloroformate and subsequent transesterification.